CVI Holdings’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

CVI Holdings’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-425,500	Closed	-$1.53M	–	468
2022 Q4	$1.53M	Hold	425,500	–	–	0.19%	158
2022 Q3	$2.74M	Buy	+425,500	New	+$3.46M	0.21%	169

Other funds holding SYRS

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

CVI Holdings's SYRS Position: Q1 2023 in Review

CVI Holdings sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2023, closing a stake of 425,500 shares — an estimated $1.53M sold.

CVI Holdings first reported a position in SYRS in Q3 2022 and held it in 2 quarters. The position peaked at $2.74M in Q3 2022. 59 funds tracked by Wall St. Rank hold SYRS as of Q1 2023.

CVI Holdings reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
CVI Holdings sold 425,500 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $1.53M.
CVI Holdings first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
CVI Holdings's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.74M in Q3 2022.
59 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.